Pfizer Inc., a global leader in the pharmaceutical market, distinguishes itself through the development, manufacture, and sale of biopharmaceutical goods. These products are derived from a variety of sources, including tissues, microorganisms, and animals, which are manipulated through biotechnological processes. Pfizer has had to adapt to a competitive, highly regulated market while maintaining a constant stream of research and development. Its primary competitors include big players such as Merck & Co. Inc., Novartis AG, Eli Lilly & Co., Bristol-Myers Squibb Co., and Johnson & Johnson.
Pfizer operates under two key segments - Biopharma and Business Innovation. In 2023, their majority revenue came from Biopharma, which deals with Primary Care, Specialty Care, and Oncology. However, in 2023, Pfizer reported a significant 41% year-over-year revenue decline to $58.5 billion, attributed to a decrease in demand for COVID-19-related products.
Despite the setback, Pfizer remains at the forefront of pharmaceutical companies in terms of revenue derived from pharma-only products. Their COVID-19 vaccine COMIRNATY, blood thinner ELIQUIS, and pneumococcal vaccine PREVNAR accounted for 42% of the company's revenue.
They've grown from manufacturing Vitamin C in the 1930s to developing life-saving medicines today, marked by notable milestones like leading the development of a COVID-19 vaccine during the pandemic. Currently, Dr. Albert Bourla leads the company as its Chairman and CEO.
In 2023, Pfizer expanded its market presence by acquiring nine new molecular entities with FDA approvals and treating approximately 618 million people worldwide with their medicines and vaccines. Their takeover of Seagen Inc has fortified their foothold in cancer drug development.
An exciting development for Pfizer has been the incorporation of mRNA technology, known for its versatility in developing the COVID-19 vaccine, which will now be employed in combating infectious diseases such as influenza and shingles. Pfizer's ongoing project, "Accord for a Healthier World", is an ambitious attempt to provide access to medicines and vaccines to 1.2 billion people in 45 lower-income countries.
Pfizer's Biopharma branch, a blend of biotechnology and pharmaceutical manufacturing, uses living organisms to combat diseases. Despite a decline in 2023 due to lesser demand for COVID-19 products, the division remains central to Pfizer's revenue generation.